NCT02331810View on ClinicalTrials.gov

Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Systemic Lupus Erythematosus
Interventions
DRUG

SAR113244

Pharmaceutical form:solution for injection Route of administration: subcutaneous

DRUG

placebo

Pharmaceutical form:solution for injection Route of administration: subcutaneous

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY